## CITATION REPORT List of articles citing

Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2

DOI: 10.1016/j.ophtha.2012.11.048 Ophthalmology, 2013, 120, 1283-91.

Source: https://exaly.com/paper-pdf/55533572/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
287	Combined rod and cone transduction by adeno-associated virus 2/8. <b>2013</b> , 24, 982-92		32
286	Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. <b>2013</b> , 21, 1976-81		13
285	Pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Experimental Eye Research, 2013, 116, 402-10	3.7	12
284	Advances in the genetics of eye diseases. <b>2013</b> , 25, 645-52		5
283	Gene therapy for hemophilia: advancing beyond the first clinical success. 2013, 20, 410-6		6
282	Gene therapy briefs. <b>2013</b> , 24, 467-9		
281	Immunology of AAV-Mediated Gene Transfer in the Eye. <b>2013</b> , 4, 261		66
280	Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment. <b>2014</b> , 2, 80-97		51
279	Cone arrestin: deciphering the structure and functions of arrestin 4 in vision. <b>2014</b> , 219, 117-31		5
278	[Molecular genetics: significance in hereditary eye diseases]. <b>2014</b> , 231, 208-9		
277	[Specific gene therapy for hereditary retinal dystrophies - an update]. <b>2014</b> , 231, 210-5		
276	Development of gene therapy for treatment of age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2014</b> , 92 Thesis3, 1-38	3.7	18
275	Overexpression of Wnt3a facilitates the proliferation and neural differentiation of neural stem cells in vitro and after transplantation into an injured rat retina. <b>2014</b> , 92, 148-61		21
274	Effective delivery of large genes to the retina by dual AAV vectors. <b>2014</b> , 6, 194-211		161
273	The Rpe65 rd12 allele exerts a semidominant negative effect on vision in mice. <b>2014</b> , 55, 2500-15		12
272	The cost of genetic testing for ocular disease: who pays?. <b>2014</b> , 25, 394-9		15
271	Should patients with ocular genetic disorders have genetic testing?. <b>2014</b> , 25, 359-65		5

270	Medical management of hereditary optic neuropathies. <b>2014</b> , 5, 141		46
269	Drug and gene delivery to the back of the eye: from bench to bedside. <b>2014</b> , 55, 2714-30		82
268	Electroporation Protocols. Methods in Molecular Biology, 2014,	1.4	8
267	Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies. <b>2014</b> , 21, 188-94		24
266	Gene therapy for the nervous system: challenges and new strategies. <b>2014</b> , 11, 817-39		58
265	The emergence of gene therapy for rare diseases. <b>2014</b> , 2, 1197-1209		2
264	Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. <b>2014</b> , 21, 450-6		69
263	Vector platforms for gene therapy of inherited retinopathies. <i>Progress in Retinal and Eye Research</i> , <b>2014</b> , 43, 108-28	20.5	106
262	Neuroprotection and Neuroregeneration for Retinal Diseases. 2014,		0
261	Chemical and material communication between the optic nerves in rats. <b>2015</b> , 43, 742-8		11
260	Retinal Hereditary and Degenerative/Dystrophic Diseases (Non-Age-Related Macular Degeneration). <b>2016</b> , 55, 205-11		4
259	Adeno-associated Virus as a Mammalian DNA Vector. <b>2015</b> , 3,		56
258	Optogenetic Approaches to Restoring Vision. <b>2015</b> , 1, 185-210		33
257	From caveman companion to medical innovator: genomic insights into the origin and evolution of domestic dogs. <b>2015</b> , 5, 239-255		2
256	A Subsequent Human Neural Progenitor Transplant into the Degenerate Retina Does Not Compromise Initial Graft Survival or Therapeutic Efficacy. <i>Translational Vision Science and Technology</i> , <b>2015</b> , 4, 7	3.3	9
255	Review and update on the molecular basis of Leber congenital amaurosis. <b>2015</b> , 3, 112-24		73
254	Adeno-associated Virus as a Mammalian DNA Vector. <b>2015</b> , 827-849		2
253	AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice. <b>2015</b> , 2, 15022		17

252	Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho(-/-) mouse. <b>2015</b> , 2, 15016	19
251	Gene therapy of inherited retinal degenerations: prospects and challenges. <b>2015</b> , 26, 193-200	35
250	Somatic Genome Manipulation. <b>2015</b> ,	1
249	Prevention of nocturnal elevation of intraocular pressure by gene transfer of dominant-negative RhoA in rats. <b>2015</b> , 133, 182-90	24
248	Retinal Gene Therapy: Current Progress and Future Prospects. <b>2015</b> , 10, 281-299	13
247	Pseudo-fovea formation after gene therapy for RPE65-LCA. <b>2014</b> , 56, 526-37	32
246	Dog models for blinding inherited retinal dystrophies. <i>Human Gene Therapy Clinical Development</i> , <b>2015</b> , 26, 15-26	36
245	Nanoparticle-based technologies for retinal gene therapy. <b>2015</b> , 95, 353-67	59
244	Gene replacement therapy for genetic hepatocellular jaundice. <b>2015</b> , 48, 243-53	16
243	The Status of RPE65 Gene Therapy Trials: Safety and Efficacy. <b>2015</b> , 5, a017285	110
242	Stem cell therapy for glaucoma: science or snake oil?. <b>2015</b> , 60, 93-105	28
241	Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation. <b>2015</b> , 26, 59-68	21
240	Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A. <b>2015</b> , 5,	20
239	Prediction of adeno-associated virus neutralizing antibody activity for clinical application. <b>2015</b> , 22, 984-92	34
238	Gene Therapy for Blinding Pediatric Eye Disorders. <b>2015</b> , 62, 185-210	2
237	Subretinal Visual Implant Alpha IMSClinical trial interim report. <b>2015</b> , 111, 149-60	250
236	Improvement and decline in vision with gene therapy in childhood blindness. 2015, 372, 1920-6	265
235	Long-term effect of gene therapy on Leberß congenital amaurosis. <b>2015</b> , 372, 1887-97	489

## (2016-2015)

234	Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 245-52	44
233	Multimodal Imaging of Central Retinal Disease Progression in a 2-Year Mean Follow-up of Retinitis Pigmentosa. <b>2015</b> , 160, 786-98.e4	67
232	Investor Outlook: Focus on Upcoming LCA2 Gene Therapy Phase III Results. <i>Human Gene Therapy Clinical Development</i> , <b>2015</b> , 26, 144-9	15
231	Gene therapy for age-related macular degeneration. <b>2015</b> , 386, 2369-70	3
230	Breakthroughs and barriers in clinical gene therapy. <b>2015</b> , 20-47	
229	Non-viral therapeutic approaches to ocular diseases: An overview and future directions. <b>2015</b> , 219, 471-487	34
228	Gene therapy returns to centre stage. <b>2015</b> , 526, 351-60	783
227	Communicating the promise for ocular gene therapies: challenges and recommendations. <b>2015</b> , 160, 408-415.e2	12
226	Pathogenic mechanisms and the prospect of gene therapy for choroideremia. <b>2015</b> , 3, 787-798	26
225	Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells. <b>2015</b> , 7, 3845-56	51
224	Treatment of ocular disorders by gene therapy. <b>2015</b> , 95, 331-42	56
223	Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. <b>2014</b> , 5, a017293	44
222	AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization. 2015, 23, 226-34	16
221	Gene therapy using stem cells. <b>2014</b> , 5,	13
220	Adeno-associated virus vectors and neurological gene therapy. <b>2015</b> , 21, 84-98	80
219	Clinical characteristics and current therapies for inherited retinal degenerations. <b>2014</b> , 5, a017111	102
218	Promising and delivering gene therapies for vision loss. <b>2015</b> , 111, 124-33	34
217	Test-Retest Variability of Fundus-Tracked Perimetry at the Peripapillary Region in Open Angle Glaucoma. <b>2016</b> , 57, 3619-25	8

216	Biophysical Properties of Optogenetic Tools and Their Application for Vision Restoration Approaches. <b>2016</b> , 10, 74		29
215	Variability and Errors of Manually Digitized Goldmann Visual Fields. <b>2016</b> , 93, 720-30		8
214	Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. <b>2016</b> , 388, 661-72	2	270
213	Span poly-L-arginine nanoparticles are efficient non-viral vectors for PRPF31 gene delivery: An approach of gene therapy to treat retinitis pigmentosa. <b>2016</b> , 12, 2251-2260		14
212	Preserved visual function in retinal dystrophy due to hypomorphic mutations. <i>British Journal of Ophthalmology</i> , <b>2016</b> , 100, 1499-1505	5.5	17
211	Emerging therapies for inherited retinal degeneration. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 368rv6	17.5	131
210	Choroideremia research: Report and perspectives on the second international scientific symposium for choroideremia. <i>Ophthalmic Genetics</i> , <b>2016</b> , 37, 267-75	1.2	12
209	Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease. <i>Progress in Retinal and Eye Research</i> , <b>2016</b> , 53, 1-20	20.5	36
208	Anti-Angiogenic Therapy in Ophthalmology. Essentials in Ophthalmology, 2016,	0.2	3
207	Single residue AAV capsid mutation improves transduction of photoreceptors in the Abca4 mouse and bipolar cells in the rd1 mouse and human retina ex vivo. <b>2016</b> , 23, 767-774		19
206	RNA Interference Prevents Autosomal-Dominant Hearing Loss. <b>2016</b> , 98, 1101-1113		66
205	Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration. <b>2016</b> , 27, 835-846		24
204	Stimulation of AAV Gene Editing via DSB Repair. <b>2016</b> , 125-137		1
203	Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration. <b>2016</b> , 14, 168-175		97
202	Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina. <b>2016</b> , 27, 580-97		55
201	Gene and cell-based therapies for inherited retinal disorders: An update. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , <b>2016</b> , 172, 349-366	3.1	50
200	Manufacturing of recombinant adeno-associated viral vectors for clinical trials. <b>2016</b> , 3, 16002		137
199	Clinical development of gene therapy: results and lessons from recent successes. <b>2016</b> , 3, 16034		146

198	Clustered Regularly Interspaced Short Palindromic Repeats: Challenges in Treating Retinal Disease.  Asia-Pacific Journal of Ophthalmology, <b>2016</b> , 5, 304-8  3.5	5
197	Evaluation of Leberß hereditary optic neuropathy patients prior to a gene therapy clinical trial. <b>2016</b> , 95, e5110	12
196	Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction. <b>2016</b> , 16, 110	6
195	Lecithin:Retinol Acyltransferase: A Key Enzyme Involved in the Retinoid (visual) Cycle. <b>2016</b> , 55, 3082-91	15
194	Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. <i>Experimental Eye Research</i> , 2016, 145, 248-257	14
193	Let There Be Light: Gene and Cell Therapy for Blindness. <b>2016</b> , 27, 134-47	91
192	Adeno-associated virus (AAV) vectors in cancer gene therapy. <b>2016</b> , 240, 287-301	90
191	Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery. <b>2016</b> , 80, 134-145	23
190	Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. <b>2016</b> , 135, 327-43	156
189	Genome Editing. 2016,	
188	Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1382, 21-39	52
187	Progress and challenges in viral vector manufacturing. <b>2016</b> , 25, R42-52	109
186	Evaluation of Ocular Gene Therapy in an Italian Patient Affected by Congenital Leber Amaurosis Type 2 Treated in Both Eyes. <b>2016</b> , 854, 533-9	1
185	SUBRETINAL CANNULATION AS A COMPLICATION OF SUTURE TRABECULOTOMY SURGERY IN A PEDIATRIC PATIENT. <b>2017</b> , 11, 79-82	1
184	Leber congenital amaurosis, from darkness to light: An ode to Irene Maumenee. <i>Ophthalmic Genetics</i> , <b>2017</b> , 38, 7-15	20
183	OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA. <b>2017</b> , 28, 15-22	13
182	Gene delivery of apoptin-derived peptide using an adeno-associated virus vector inhibits glioma and prolongs animal survival. <b>2017</b> , 482, 506-513	6
181	Gene therapies development: slow progress and promising prospect. <b>2017</b> , 5, 1265293	68

180	[Optogenetics: A Therapeutic Option for Advanced Retinal Dystrophies]. <b>2017</b> , 234, 335-342	1
179	Genetic and phenotypic characteristics of four Chinese families with fundus albipunctatus. <b>2017</b> , 7, 46285	13
178	CLINICAL PRESENTATION AND DISEASE COURSE OF USHER SYNDROME BECAUSE OF MUTATIONS IN MYO7A OR USH2A. <b>2017</b> , 37, 1581-1590	22
177	Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward. <b>2017</b> , 25, 1076-1094	67
176	Electronic retinal implants and artificial vision: journey and present. 2017, 31, 1383-1398	69
175	Genetic Engineering and Manufacturing of Hematopoietic Stem Cells. <b>2017</b> , 5, 96-105	15
174	Patient-specific induced pluripotent stem cells to evaluate the pathophysiology of TRNT1-associated Retinitis pigmentosa. <b>2017</b> , 21, 58-70	38
173	Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. <b>2017</b> , 24, 290-297	21
172	Gene Therapy 2017: Progress and Future Directions. 2017, 10, 242-248	89
171	Spectral-domain optical coherence tomography findings in Alstrfh syndrome. <i>Ophthalmic Genetics</i> , <b>2017</b> , 38, 440-445	4
171 170		32
	<b>2017</b> , 38, 440-445	
170	2017, 38, 440-445  Ciliopathies: Genetics in Pediatric Medicine. 2017, 6, 18-29	32
170 169	2017, 38, 440-445  Ciliopathies: Genetics in Pediatric Medicine. 2017, 6, 18-29  Gene therapy for inherited retinal degenerations: initial successes and future challenges. 2017, 14, 051002  Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal	32
170 169 168	Ciliopathies: Genetics in Pediatric Medicine. 2017, 6, 18-29  Gene therapy for inherited retinal degenerations: initial successes and future challenges. 2017, 14, 051002  Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases. 2017, 58, 217-226  Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in	32 16 64
170 169 168	Ciliopathies: Genetics in Pediatric Medicine. 2017, 6, 18-29  Gene therapy for inherited retinal degenerations: initial successes and future challenges. 2017, 14, 051002  Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases. 2017, 58, 217-226  Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates. 2017, 188, 40-57.e4	32 16 64 12
170 169 168 167 166	Ciliopathies: Genetics in Pediatric Medicine. 2017, 6, 18-29  Gene therapy for inherited retinal degenerations: initial successes and future challenges. 2017, 14, 051002  Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases. 2017, 58, 217-226  Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates. 2017, 188, 40-57.e4  Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3. 2017, 390, 823-824  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated	32 16 64 12

## (2018-2017)

162	Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. <i>British Journal of Ophthalmology</i> , <b>2017</b> , 101, 1147-1154	5.5	146
161	Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. <b>2017</b> , 31, 317-334		466
160	Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina. <b>2017</b> , 28, 154-167		77
159	Gene and Cell Therapy for Inborn Errors of Metabolism. <b>2017</b> , 155-171		1
158	Available Evidence on Leber Congenital Amaurosis and Gene Therapy. <b>2017</b> , 32, 14-21		8
157	Correction of Monogenic and Common Retinal Disorders with Gene Therapy. 2017, 8,		29
156	Gene Manipulation Strategies to Identify Molecular Regulators of Axon Regeneration in the Central Nervous System. <b>2017</b> , 11, 231		12
155	Gene Transfer in Spinal Muscular Atrophy. <b>2017</b> , 313-323		
154	Precision medicine in hearing loss. <b>2018</b> , 45, 99-109		10
153	Retinal gene therapy. <b>2018</b> , 126, 13-25		35
152	Prevention of Photoreceptor Cell Loss in a Cln6 Mouse Model of Batten Disease Requires CLN6 Gene Transfer to Bipolar Cells. <b>2018</b> , 26, 1343-1353		27
151	OPA1: How much do we know to approach therapy?. <b>2018</b> , 131, 199-210		29
150	Gene therapy for Leber congenital amaurosis. <b>2018</b> , 13, 11-15		3
149	Therapeutic avenues for hereditary forms of retinal blindness. <i>Journal of Genetics</i> , <b>2018</b> , 97, 341-352	1.2	10
148	Triple Vectors Expand AAV Transfer Capacity in the Retina. 2018, 26, 524-541		68
147	Assessment of AAV Vector Tropisms for Mouse and Human Pluripotent Stem Cell-Derived RPE and Photoreceptor Cells. <b>2018</b> , 29, 1124-1139		36
146	CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration. <i>Progress in Retinal and Eye Research</i> , <b>2018</b> , 65, 28-49	20.5	43
145	High-Throughput Screening Identifies Kinase Inhibitors That Increase Dual Adeno-Associated Viral Vector Transduction In Vitro and in Mouse Retina. <b>2018</b> , 29, 886-901		8

144	Leber® Congenital Amaurosis and Gene Therapy. 2018, 85, 237-242		7
143	Gene therapy for inherited retinal and optic nerve degenerations. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 37-49	5-4	55
142	Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis. <b>2018</b> , 26, 256-268		63
141	Retinal Gene Therapy. <i>Methods in Molecular Biology</i> , <b>2018</b> ,	1.4	5
140	Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1715, 225-238	1.4	8
139	Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery. <b>2018</b> , 34, 141-153		34
138	Ganglion cell-inner plexiform layer and retinal nerve fibre layer changes within the macula in retinitis pigmentosa: a spectral domain optical coherence tomography study. <i>Acta Ophthalmologica</i> , <b>2018</b> , 96, e180-e188	3.7	10
137	A Cross-Sectional and Longitudinal Study of Retinal Sensitivity in RPE65-Associated Leber Congenital Amaurosis. <b>2018</b> , 59, 3330-3339		16
136	Genetics of the Retinal Dystrophies. <b>2018</b> , 1-10		
135	Surgical Removal of Internal Limiting Membrane and Layering of AAV Vector on the Retina Under Air Enhances Gene Transfection in a Nonhuman Primate. <b>2018</b> , 59, 3574-3583		17
134	Retinitis pigmentosa: recent advances and future directions in diagnosis and management. <b>2018</b> , 30, 725-733		30
133	Intravitreal Injection of AAV Expressing Soluble VEGF Receptor-1 Variant Induces Anti-VEGF Activity and Suppresses Choroidal Neovascularization. <b>2018</b> , 59, 5398-5407		6
132	Revolution in Gene Medicine Therapy and Genome Surgery. <b>2018</b> , 9,		17
131	Severe Loss of Tritan Color Discrimination in RPE65 Associated Leber Congenital Amaurosis. <b>2018</b> , 59, 85-93		11
130	High-Frequency Stimulation of Normal and Blind Mouse Retinas Using TiO2 Nanotubes. <b>2018</b> , 28, 180463	39	11
129	Gene Therapy for Inherited Retinopathies: Update on Development Progress. <b>2018</b> , 2, 219-226		
128	The Progress of Gene Therapy for Leberß Optic Hereditary Neuropathy. <i>Current Gene Therapy</i> , <b>2017</b> , 17, 320-326	4.3	10
127	The ABCs of Gene Cloning. 2018,		1

126	Analysis of Visual Field Defects Obtained with Semiautomated Kinetic Perimetry in Patients with Leber Hereditary Optic Neuropathy. <b>2018</b> , 2018, 5985702		2
125	Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. <i>Ophthalmic Genetics</i> , <b>2018</b> , 39, 544-549		16
124	Choroideremia: molecular mechanisms and development of AAV gene therapy. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 807-820	-	22
123	Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success. <b>2018</b> , 11, 221		27
122	Nanotechnology for ocular drug delivery. <b>2018</b> , 137-188		8
121	FGF21 gene therapy as treatment for obesity and insulin resistance. <b>2018</b> , 10,		100
120	Seeing the Light after 25 Years of Retinal Gene Therapy. <b>2018</b> , 24, 669-681		65
119	Emerging Gene Therapy Treatments for Inherited Retinal Diseases. 2018, 49, 472-478		2
118	Angiotensin 1-7 Overexpression Mediated by a Capsid-optimized AAV8 Vector Leads to Significant Growth Inhibition of Hepatocellular Carcinoma. <b>2018</b> , 14, 57-68		11
117	Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. <b>2018</b> , 29, 1428-1437		31
116	Cost-effectiveness of Voretigene Neparvovec-rzyl Therapy. <b>2019</b> , 137, 1123-1124		2
115	Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease. <b>2019</b> , 137, 1115-1123		26
114	Stellungnahme von DOG, RG und BVA zur therapeutischen Anwendung von voretigene neparvovec (Luxturna¶in der Augenheilkunde. <b>2019</b> , 236, 816-824		1
113	Has retinal gene therapy come of age? From bench to bedside and back to bench. <b>2019</b> , 28, R108-R118		28
112	Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. <b>2019</b> , 24, 1685-1693		42
111	Evaluation of AAV-mediated delivery of shRNA to target basal-like breast cancer genetic vulnerabilities. <b>2019</b> , 300, 70-77		8
110	An update on gene therapy for lysosomal storage disorders. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 655-670		22
109	[Statement of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the Professional Association of German Ophthalmologists (BVA) on the therapeutic use of voretigene neparvovec-rzyl (Luxturna) in ophthalmology: Situation January 2019]. <b>2019</b> , 116, 524-533		O

108	Detailed clinical characterisation, unique features and natural history of autosomal recessive -associated retinal degeneration. <i>British Journal of Ophthalmology</i> , <b>2019</b> , 103, 1789-1796	5.5	15
107	Gene Therapy in Retinal Dystrophies. International Journal of Molecular Sciences, 2019, 20,	6.3	45
106	Investigation and Restoration of BEST1 Activity in Patient-derived RPEs with Dominant Mutations. <b>2019</b> , 9, 19026		15
105	Outcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice. <b>2019</b> , 10, 1076		17
104	Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye. <b>2018</b> , 36, 29		88
103	Leber Congenital Amaurosis in Asia. Essentials in Ophthalmology, <b>2019</b> , 191-231	0.2	
102	Transplantation of photoreceptors into the degenerative retina: Current state and future perspectives. <i>Progress in Retinal and Eye Research</i> , <b>2019</b> , 69, 1-37	20.5	74
101	Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations. <b>2019</b> , 47, 521-536		24
100	Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. <b>2019</b> , 22, 161-167		33
99	Retinal Degeneration. <i>Methods in Molecular Biology</i> , <b>2019</b> ,	1.4	3
98	Optimized Subretinal Injection Technique for Gene Therapy Approaches. <i>Methods in Molecular Biology</i> , <b>2019</b> , 1834, 405-412	1.4	4
97	Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna) in ophthalmology. English version: January 2019. <b>2020</b> , 117, 16-24		3
96	Current Concepts in Ophthalmology. <b>2020</b> ,		
95	AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. <b>2020</b> , 28, 723-746	5	137
94	PHENOTYPIC CHARACTERISTICS OF ROD-CONE DYSTROPHY ASSOCIATED WITH MYO7A MUTATIONS IN A LARGE FRENCH COHORT. <b>2020</b> , 40, 1603-1615		8
93	Rewriting the Future: Promises and Limits of Germline Gene Editing in Craniofacial Surgery. <b>2020</b> , 31, 1517-1520		
92	Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence. <b>2020</b> , 14, 3855-3	869	8
91	Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders. <b>2020</b> , 11, 556610		2

90	Targeting the photoreceptor cilium for the treatment of retinal diseases. <b>2020</b> , 41, 1410-1415		4
89	Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review. <b>2020</b> , 9, 709-724		12
88	Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration. <b>2020</b> , 34, 763-781		11
87	The new landscape of retinal gene therapy. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , <b>2020</b> , 184, 846-859	3.1	9
86	Voretigene Neparvovec and Gene Therapy for Leberß Congenital Amaurosis: Review of Evidence to Date. <i>The Application of Clinical Genetics</i> , <b>2020</b> , 13, 179-208	3.1	2
85	Compound heterozygous RPE65 mutations associated with an early onset autosomal recessive retinitis pigmentosa. <i>Journal of Gene Medicine</i> , <b>2020</b> , 22, e3211	3.5	4
84	Future Vision 2020 and Beyond-5 Critical Trends in Eye Research. <i>Asia-Pacific Journal of Ophthalmology</i> , <b>2020</b> , 9, 180-185	3.5	2
83	Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies. <i>Journal of Applied Genetics</i> , <b>2020</b> , 61, 179-186	2.5	1
82	Voretigene neparvovec-rzyl for treatment of -mediated inherited retinal diseases: a model for ocular gene therapy development. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 565-578	5.4	20
81	Emerging Approaches for Restoration of Hearing and Vision. <i>Physiological Reviews</i> , <b>2020</b> , 100, 1467-15	5 <b>25</b> 47.9	26
80	The effect of human gene therapy for RPE65-associated Leberß congenital amaurosis on visual function: a systematic review and meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 49	4.2	17
79	AAV-expressed G protein induces robust humoral and cellular immune response and provides durable protection from rabies virus challenges in mice. <i>Veterinary Microbiology</i> , <b>2020</b> , 242, 108578	3.3	5
78	Diagnostic and therapeutic applications of genomic medicine in progressive, late-onset, nonsyndromic sensorineural hearing loss. <i>Gene</i> , <b>2020</b> , 747, 144677	3.8	2
78 77		3.8 5.5	2
	nonsyndromic sensorineural hearing loss. <i>Gene</i> , <b>2020</b> , 747, 144677  Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future		
77	nonsyndromic sensorineural hearing loss. <i>Gene</i> , <b>2020</b> , 747, 144677  Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. <i>British Journal of Ophthalmology</i> , <b>2021</b> , 105, 151-157  Advances in the development of gene therapy, noncoding RNA, and exosome-based treatments for	5.5	21
77 76	nonsyndromic sensorineural hearing loss. <i>Gene</i> , <b>2020</b> , 747, 144677  Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. <i>British Journal of Ophthalmology</i> , <b>2021</b> , 105, 151-157  Advances in the development of gene therapy, noncoding RNA, and exosome-based treatments for tendinopathy. <i>Annals of the New York Academy of Sciences</i> , <b>2021</b> , 1490, 3-12  Targeted tPA overexpression in denervated spinal motor neurons promotes stroke recovery in	5.5 6.5	21

72	Genotype <b>P</b> henotype of RPE65 Mutations: A Reference Guide for Gene Testing and Its Clinical Application. <i>Essentials in Ophthalmology</i> , <b>2021</b> , 181-196	0.2	
71	Gene Therapy in the Treatment of Geographic Atrophy. <i>International Ophthalmology Clinics</i> , <b>2021</b> , 61, 241-247	1.7	
70	PrWentionsfalle und Selbstschreck. Karger Kompass Ophthalmologie, <b>2021</b> , 7, 112-112	0	
69	Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec. <i>British Journal of Ophthalmology</i> , <b>2021</b> ,	5.5	3
68	Rümliche und zeitliche Aufl\u00edung der Wiederherstellungsdynamik der Photorezeptoren nach Behandlung mit Voretigen Neparvovec. <i>Karger Kompass Ophthalmologie</i> , <b>2021</b> , 7, 154-163	О	
67	Administration of Ocular Gene Therapy. International Ophthalmology Clinics, 2021, 61, 131-149	1.7	
66	Stem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art. <i>JARO - Journal of the Association for Research in Otolaryngology</i> , <b>2021</b> , 22, 95-105	3.3	4
65	Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	4
64	Gene Therapy to the Retina and the Cochlea. Frontiers in Neuroscience, 2021, 15, 652215	5.1	5
63	An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	10
62	A Systematic Review and Meta-Analyses of Interventional Clinical Trial Studies for Gene Therapies for the Inherited Retinal Degenerations (IRDs). <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	2
61	Directed Evolution of AAV Targeting Primate Retina by Intravitreal Injection Identifies R100, a Variant Demonstrating Robust Gene Delivery and Therapeutic Efficacy in Non-Human Primates.		O
60	Paired box 6 programs essential exocytotic genes in the regulation of glucose-stimulated insulin secretion and glucose homeostasis. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	0
59	RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 257	4.2	9
58	Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec. <i>Acta Ophthalmologica</i> , <b>2021</b> ,	3.7	1
57	Gene therapy for inherited retinal diseases. Annals of Translational Medicine, 2021, 9, 1278	3.2	5
56	Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: A comprehensive review. <i>Future Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 7,	2.1	1
55	Voretigene Neparvovec Gene Therapy in Clinical Practice: Treatment of the First Two Italian Pediatric Patients. <i>Translational Vision Science and Technology</i> , <b>2021</b> , 10, 11	3.3	2

54	Creating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases. <i>Asia-Pacific Journal of Ophthalmology</i> , <b>2021</b> , 10, 5-11	3.5	3
53	Suprachoroidal Delivery of Subretinal Gene and Cell Therapy. <b>2021</b> , 141-153		
52	Genes and Gene Therapy in Inherited Retinal Disease. International Ophthalmology Clinics, 2021, 61, 3-4	<b>15</b> 1.7	
51	Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders. <i>Open Life Sciences</i> , <b>2021</b> , 16, 431-441	1.2	1
50	Gene Therapy in the Cornea. 1-9		1
49	DNA delivery in adult mouse eyes: an update with corneal outcomes. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1121, 165-77	1.4	4
48	The Apparently Blind Infant. <b>2016</b> , 1-74		О
47	Toward a Novel Medical Device Based on Chromatic Pupillometry for Screening and Monitoring of Inherited Ocular Disease: A Pilot Study. <i>IFMBE Proceedings</i> , <b>2019</b> , 387-390	0.2	4
46	Preclinical models to assess the immunogenicity of AAV vectors. <i>Cellular Immunology</i> , <b>2019</b> , 342, 10372	224.4	7
45	retinopathy: clinical features, molecular genetics and directions for future therapy. <i>Ophthalmic Genetics</i> , <b>2020</b> , 41, 208-215	1.2	15
44	CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). <i>JCI Insight</i> , <b>2016</b> , 1, e86696	9.9	34
43	Halting progressive neurodegeneration in advanced retinitis pigmentosa. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 3704-13	15.9	49
42	Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 4659-4673	15.9	52
41	The frequency-response electroretinogram distinguishes cone and abnormal rod function in rd12 mice. <i>PLoS ONE</i> , <b>2015</b> , 10, e0117570	3.7	10
40	Recent Advancements in Gene Therapy for Hereditary Retinal Dystrophies. <i>Tak Oftalmoloji Dergisi</i> , <b>2017</b> , 47, 338-343	1.2	13
39	CRISPR Systems Suitable for Single AAV Vector Delivery. Current Gene Therapy, 2021,	4.3	1
38	Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 750586	4.9	3
37	Neuroprotection for Photoreceptors. <b>2014</b> , 191-204		

36 Leber Congenital Amaurosis and Early-Onset Retinal Dystrophy. **2014**, 121-133

35	Future Therapies for Retinitis Pigmentosa. <b>2014</b> , 467-481		
34	Viral Vectors for Gene Therapy. 1-16		
33	Gene Therapy for Choroideremia. <i>Essentials in Ophthalmology</i> , <b>2015</b> , 27-41	0.2	
32	Dog Models for Blinding Inherited Retinal Degenerations. <i>Human Gene Therapy Clinical Development</i> , 150127063140004	3.2	
31	Somatic Gene Therapy Using Viral Vectors: Theoretical and Clinical Implications in Relation to Treatment of Genetic Conditions in Humans. <b>2015</b> , 35-67		
30	Anti-Angiogenic Gene Therapy: Basic Science and Challenges for Translation into the Clinic. <i>Essentials in Ophthalmology</i> , <b>2016</b> , 173-188	0.2	
29	Leber Congenital Amaurosis/Early-Onset Retinal Dystrophy in Japanese Population. <i>Essentials in Ophthalmology</i> , <b>2017</b> , 137-167	0.2	
28	Gene Therapy and Surgery for Retinal Diseases. 1-10		
27	The inborn errors of metabolism: General aspects. <b>2020</b> , 1929-1941		
26	Gene Therapy Approaches for Cochlear Repair. <b>2020</b> , 962-984		
25	Employing nonhomologous end joining and homology-directed repair for treatment of Leber congenital amaurosis and inherited retinal degeneration. <b>2022</b> , 101-110		1
24	Recent Developments in Vitreo-Retinal Surgery. <b>2020</b> , 165-199		1
23	The clinical features of retinal disease due to a dominant mutation in RPE65. <i>Molecular Vision</i> , <b>2016</b> , 22, 626-35	2.3	28
22	Insights from Genetic Model Systems of Retinal Degeneration: Role of Epsins in Retinal Angiogenesis and VEGFR2 Signaling. <i>Journal of Nature and Science</i> , <b>2017</b> , 3,		5
21	Early onset flecked retinal dystrophy associated with new compound heterozygous variants. <i>Molecular Vision</i> , <b>2018</b> , 24, 286-296	2.3	11
20	The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic review <i>Genetics in Medicine</i> , <b>2021</b> ,	8.1	1
19	RPE based gene and cell therapy for inherited retinal diseases: A review <i>Experimental Eye Research</i> , <b>2022</b> , 217, 108961	3.7	O

Molecular Genetics of Inherited Retinal Diseases. **2022**, 1-19

17	Stem Cell and Gene Therapy for Inherited Retinal Diseases. <b>2022</b> , 39-67		
16	It is time for a moonshot to find "Cures" for diabetic retinal disease <i>Progress in Retinal and Eye Research</i> , <b>2022</b> , 101051	20.5	0
15	Therapeutic avenues for hereditary forms of retinal blindness. <i>Journal of Genetics</i> , <b>2018</b> , 97, 341-352	1.2	6
14	Table_1.XLSX. <b>2018</b> ,		
13	Table_2.XLSX. <b>2018</b> ,		
12	Presentation_1.pptx. <b>2019</b> ,		
11	Table_1.docx. <b>2019</b> ,		
10	Essential cues of engineered polymeric materials regulating gene transfer pathways. <i>Progress in Materials Science</i> , <b>2022</b> , 128, 100961	42.2	1
9	Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs. <i>Antiviral Research</i> , <b>2022</b> , 204, 105366	10.8	1
8	Using analogue data to substantiate long-term durability of gene therapies: a narrative review. <i>Regenerative Medicine</i> ,	2.5	
7	LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea. <b>2022</b> , 350, 401-413		0
6	Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease. <b>2022</b> , 11, 380-39	1	О
5	Therapy with voretigene neparvovec. How to measure success?. <b>2022</b> , 101115		0
4	Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy. <b>2022</b> , 12,		О
3	Gene Therapy with Voretigene Neparvovec Improves Vision and Partially Restores Electrophysiological Function in Pre-School Children with Leber Congenital Amaurosis. <b>2023</b> , 11, 103		1
2	High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector. <b>2023</b> , 15, 64		2
1	CRISPR-mediated optogene expression from a cell-specific endogenous promoter in retinal ON-bipolar cells to restore vision. 3,		O